Back to results
US 12,064,450 B2Granted
Tumoricidal and antimicrobial compositions and methods
AssigneeImmunityBio, Inc.
InventorsHans G. Klingemann, Barry J. Simon
Life of this patent
Estimating the term…
Abstract
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Claims11
A production intermediate for a cell-based product, comprising:
- a plurality of NK-92 cells in a culture medium comprising (i) IL-15, and (ii) L-asparagine, L-glutamine, and L-serine;
- wherein the NK-92 cells are a subpopulation of wild type NK-92 cells or modified NK-92 cells, wherein the subpopulation of the modified NK-92 cells have been modified to express (i) an Fc receptor selected from the group consisting of an Fcγ receptor, CD16 (FcγRIII-A), FCγRI (CD64), FCγRII (CD32), FCγRIII, FcRn, Fcα, and Fcε;
- or (ii) CD16, CD16-γ, or CD16-C;
- or (iii) IL-2, an IL-2 receptor, IL-15, an IL-15 receptor, IL-18, an IL-18 receptor, IL-21, and/or an IL-21 receptor;
- wherein the subpopulation of wild type NK-92 cells or modified NK-92 cells produces cytotoxic exosomes when grown in the culture medium;
- and
- wherein the culture medium comprises exosomes and/or microvesicles that were produced by the subpopulation of wild type NK-92 cells or modified NK-92 cells in the culture medium.
4 more elements
A production intermediate for a cell-based product, comprising:
- a plurality of NK-92 cells in a culture medium comprising (i) IL-2 and one or more additional cytokines, and (ii) L-asparagine, L-glutamine, and L-serine;
- wherein the NK-92 cells are a subpopulation of wild type NK-92 cells or modified cells, wherein the subpopulation of the modified NK-92 cells have been modified to express (i) an Fc receptor selected from the group consisting of an Fcγ receptor, CD16 (FcγRIII-A), FcγRI (CD64), FcγRII (CD32), FcγRIII, FcRn, Fcα, and Fcε;
- or (ii) CD16, CD16-γ, or CD16-ζ;
- or (iii) IL-2, and IL-2 receptor, IL-15, an IL-15 receptor, IL-18, an IL-18 receptor, IL-21, and/or an IL-21 receptor;
- wherein the subpopulation of wild type NK-92 cells or modified NK-92 cells produce cytotoxic exosomes when grown in the culture medium;
- and
- wherein the culture medium comprises exosomes and/or microvesicles that were produced by the subpopulation of wild type NK-92 cells or modified NK-92 cells in the culture medium.
4 more elements
Dependencies are inferred from the claim text.